$0.615
-0.000 (-0.03%)收盘时
BBLG 资讯
BBLG 事件
Bone Biologics Extends rhNELL-1 Protein Shelf Life to 32 Months
Bone Biologics announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. "Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribute rhNELL-1 as we prepare for pivotal-study scale," said Jeff Frelick, Chief Executive Officer. "We have achieved each stability milestone on the timeline communicated to shareholders. By extending the period the product can be held before use, we believe this milestone supports more efficient lot sizing, inventory management and distribution planning as our first-in-human NB1 study advances toward completion of enrollment."
Bone Biologics Files to Sell 6.46M Shares of Common Stock
Bone Biologics files to sell 6.46M shares of common stock for holders
Bone Biologics Enters Agreement to Issue 2,112,677 Shares with Institutional Investor
Bone Biologics announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 2,112,677 shares of common stock (or pre-funded warrants in lieu thereof), Series F warrants to purchase up to 2,112,677 shares of common stock and short-term Series G warrants to purchase up to 2,112,677 shares of common stock at a purchase price of $1.42 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 29 Months
Bone Biologics announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the company progresses rhNELL-1 toward the manufacturing scale required for a future pivotal study.
Bone Biologics Summarizes 2025 Milestones and 2026 Outlook
Bone Biologics summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. 2025 Highlights: Extended rhNELL-1 Product Shelf Life; SCompleted a registered public offering for total gross proceeds of $5 million during the second quarter of 2025; filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1; regained compliance with Nasdaq's minimum bid price requirement. Outlook for 2026: Clinical Development Progression - Continuing advancement of NB1, the Company's rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate; Operational and Manufacturing Execution - Ongoing efforts to support regulatory readiness and future commercialization planning; Intellectual Property Strategy - Continuing pursuit of relevant patent protections to enhance long-term platform value; Financial Discipline and Strategic Focus - Maintaining prudent capital management while supporting scientific progress and shareholder engagement.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。